The c-Myc induced murine HCC will serve as an excellent preclinical model to evaluate the therapeutic potential of FASN inhibitor for HCC treatment, either alone or in combination with other chemotherapeutic agents. This evidence concerns the gene FASN and hepatocellular carcinoma.